Management Quality -- 7/10
MDT management earns a 7/10 driven by Geoff Martha delivering 10+ consecutive quarters of mid-single-digit
organic revenue growth, building the CAS/PFA franchise from near-zero to $1B+ run-rate (80% YoY growth in
Q3 FY26), and accelerating product approvals across the portfolio. Promise delivery rate is strong: 6 of 11
met or exceeded, 4 on track, 1 partially met, 0 broken. The score is held back by: (1) operating margin
expansion that remains elusive despite revenue acceleration, (2) Hugo robotic surgery still pre-revenue in the
U.S. after years of delays, and (3) MedSurg segment stuck at 1-3% organic growth.
Weight: 20%
Promise-Keeping Rate
6/11 MET OR EXCEEDED
4 on track | 1 partial | 0 broken | Guidance consistently met or beaten
FY25 Organic Growth
5.0% (MSD Target Met)
FY26 tracking ~5.5% guided | 10+ consecutive quarters MSD+
CAS/PFA Revenue Growth
80% YoY (Q3 FY26)
From near-zero to $1B+ run-rate | On track to $2B by H1 FY27
FY25 EPS Actual
$5.47 (In Raised Range)
Guided $5.44-$5.50 | 9% back-half EPS growth as promised
Leadership team
Geoff Martha -- Chairman & CEO (since Apr 2020)
Internal promotion from Strategy & Business Development. Not a founder but a turnaround operator.
Inherited a company that had been a serial underperformer for ~5 years under prior leadership with
flat-to-low-single-digit organic growth and no margin leverage. Has re-energized the innovation engine
and commercial execution across the portfolio.
Thierry Pieton -- CFO (since Q4 FY25)
Permanent CFO replacing Gary Corona (interim ~1 year). Ex-automotive background brings operational rigor
and M&A/divestiture expertise. This is a credibility-building hire with a clear operational mandate.
Two CFOs in two years introduces some continuity risk, though the transition appears orderly and Pieton
is viewed positively.
Key Changes & Governance
Sean Salmon (EVP, Cardiovascular) departed after Q4 FY25; replaced internally by Skip Kiil.
Que Dallara named CEO-designate of MiniMed (Diabetes spinoff).
Board refresh (Q1 FY26): Elliott Management partnership added two new independent directors
(John Groetelaars, Bill Jellison) and two new committees (Growth, Operating). Investor Day planned mid-CY26.
Activist involvement from Elliott Management adds urgency and accountability. Board refresh is a positive
governance signal. Leadership transitions appear orderly, not crisis-driven.
Promise vs. delivery tracker (11 promises)
| When Promised | Promise | Evidence | Grade |
|---|---|---|---|
| Q2 FY25 | Organic growth 5%+ durable (MSD) | FY25: 5.0%. FY26 Q1: 4.8%, Q2: 5.5%, Q3: 6.0%. Guided ~5.5% full FY26. 10+ consecutive quarters MSD. | MET |
| Q2 FY25 | CAS double-digit growth in Q3 FY25 | CAS grew ~25% Q3 FY25, then ~30% Q4, ~50% Q1 FY26, 71% Q2, 80% Q3 FY26. Massively exceeded. | EXCEEDED |
| Q4 FY25 | CAS $2B trailing revenue by H1 FY27 | On track per Q3 FY26: remain on track to double revenue, delivering $2B trailing by H1 FY27. | ON TRACK |
| Q2 FY25 | Hugo FDA urology submission Q1 CY25 | Filed in Q4 FY25. FDA clearance received Q3 FY26 (Jan 2026). First cases at Cleveland Clinic. Slight delay on filing. | MET (slight delay) |
| Q2 FY25 | FY25 EPS guidance $5.44-$5.50 (raised) | FY25 actual: $5.47. Delivered within raised range. Q3 and Q4 showed strong 9% back-half EPS growth. | MET |
| Q4 FY25 | FY26 EPS $5.50-$5.60, raised to $5.62-$5.66 | Through Q3 FY26: $3.98. Need ~$1.66 in Q4 (historically strongest). Tracking to midpoint. | ON TRACK |
| Q4 FY25 | FY27 high-single-digit EPS growth | Reiterated consistently through Q3 FY26. Supported by diabetes separation, CAS mix, FX turning neutral. | FUTURE |
| Ongoing | Operating margin expansion | FY26 op margin guided roughly flat incl. tariffs. Q4 FY25 was 27.8% (up 90bps YoY). Heavy investment cycle weighing. | PARTIAL |
| Q4 FY25 | Diabetes separation by end CY26 | Q3 FY26: perfectly on track. MiniMed Flex submitted to FDA. Fit patch pump on track for fall submission. | ON TRACK |
| Q4 FY25 | Simplera Sync U.S. launch Fall 2025 | Launched Dec 2025 (Q3 FY26). Slightly late but delivered. Combined with Instinct drove 35K+ U.S. orders. | MET (slightly late) |
| Q4 FY25 | Symplicity NCD from CMS by Oct 2025 | NCD finalized ~Oct 2025. Broader than proposed. Commercial payers coming online faster than anticipated. | MET |
Of 11 promises tracked, 6 fully met or exceeded, 4 on track or future, 1 partially met. No broken promises in
the review period. CAS/PFA promises have been massively exceeded. Guidance has been met or beaten consistently.
Source: Daloopa, earnings call transcripts Q2 FY25 - Q3 FY26.
Execution assessment
Organic Growth Re-acceleration -- Strong
From low-single-digit pre-Martha to 10 consecutive quarters of MSD+ growth. This is the core turnaround
thesis and it is working. FY25 delivered 5.0% organic; FY26 tracking ~5.5% with Q3 at 6.0%.
CAS/PFA Franchise -- Home Run
From near-zero to $1B+ run-rate in ~18 months. 80% YoY growth in Q3 FY26 with significant share gains.
Sphere-9 catheter is differentiated. Pipeline (Sphere-360) extends the runway. On track to double
to $2B trailing by H1 FY27.
Product Approval Cadence -- Accelerating
Aurora EV-ICD (doubling YoY), Hugo FDA clearance, Simplera Sync, Instinct sensor, BrainSense adaptive DBS,
Altaviva, Stealth AXiS -- management is converting pipeline into approvals at an accelerating rate.
Strategic Portfolio Moves -- Smart
Diabetes separation is the right call -- removes a low-margin B2C business, simplifies the portfolio,
creates EPS accretion via share retirement. Elliott partnership adds governance rigor. Performance-driven
culture change with centralized global operations.
Operating Margin Expansion -- Disappointing
Despite revenue acceleration, operating margins have not expanded meaningfully on a reported basis. FY26
guided roughly flat (down ~50bps incl. tariffs). Heavy investment cycle is the explanation, but the
question persists. Tax rate stepped up from ~15% to ~18% (Pillar Two), eating 300bps of EPS growth.
Hugo & MedSurg -- Still Waiting
Hugo only just received FDA clearance in Jan 2026 after years of development. First U.S. cases just
completed but revenue contribution remains minimal. MedSurg stuck at 1-3% organic growth for 6+ quarters.
Structural Heart showing early competitive pressure in U.S. TAVR.
Red flags check
| Flag | Status | Detail |
|---|---|---|
| Missed guidance / lowered estimates | NO | Have met or beaten guidance every quarter in the review period. Raised guidance multiple times. |
| Aggressive accounting | LOW RISK | Standard med-tech GAAP-to-non-GAAP adjustments (restructuring, amortization). No unusual items flagged. |
| Executive turnover | MODERATE | CFO transition (Corona to Pieton), CVP departure (Salmon), IR head changed. Appear orderly, not crisis-driven. |
| Promotional tone / overpromise | LOW-MOD | Martha is consistently optimistic but has largely backed it up. CAS promises exceeded. Some unproven language around Symplicity/Altaviva. |
| Capital allocation concerns | LOW | $6.3B returned to shareholders in FY25. Dividend increased 48th consecutive year. Tuck-in M&A disciplined (CathWorks, Anteris). |
| Guidance sandbagging | MODERATE | Martha/Pieton appear to guide conservatively and beat. Positive trait but 5% organic target has been consistently achievable. |
| Structural Heart momentum | WATCH | Q3 FY26 grew only low-single-digits with competitive pressure in U.S. TAVR. Large, high-margin franchise that needs to hold. |
No major red flags. Executive turnover is moderate but orderly. Watch items include Structural Heart competitive
pressure, Hugo revenue ramp timing, and margin delivery on a reported basis.
Score rationale
7/10. Martha is a competent turnaround operator who has re-energized the innovation engine
and commercial execution. The organic growth re-acceleration is real and diversified -- 10+ quarters of MSD.
CAS/PFA is a genuine franchise-building achievement where promises have been exceeded. Product approval
cadence is strong and accelerating. Strategic decisions (Diabetes separation, Elliott partnership, board
refresh) show good judgment. Guidance has been met or exceeded consistently with no credibility gaps.
Why not higher (8-9): (1) Operating margin expansion has been promised for years but remains elusive on a reported basis -- the investment phase explanation is reasonable but getting long in the tooth. (2) Hugo has been a multi-year story with repeated timeline pushbacks; now launched in the U.S. but revenue contribution is still negligible. (3) MedSurg segment remains a drag with no clear catalyst until Hugo scales. (4) Structural Heart showing early signs of competitive pressure.
What would move this to 8: Consistent reported operating margin expansion over 2-3 quarters. Hugo generating meaningful U.S. revenue contribution. MedSurg organic growth re-accelerating above 3%. Successful execution of Diabetes separation on time. FY27 high-single-digit EPS growth delivered as promised.
Why not higher (8-9): (1) Operating margin expansion has been promised for years but remains elusive on a reported basis -- the investment phase explanation is reasonable but getting long in the tooth. (2) Hugo has been a multi-year story with repeated timeline pushbacks; now launched in the U.S. but revenue contribution is still negligible. (3) MedSurg segment remains a drag with no clear catalyst until Hugo scales. (4) Structural Heart showing early signs of competitive pressure.
What would move this to 8: Consistent reported operating margin expansion over 2-3 quarters. Hugo generating meaningful U.S. revenue contribution. MedSurg organic growth re-accelerating above 3%. Successful execution of Diabetes separation on time. FY27 high-single-digit EPS growth delivered as promised.
Data sourced from Daloopa and earnings call transcripts Q2 FY25 - Q3 FY26.